Increase of serum CA19-9 level without an evident lesion on conventional imaging is insufficient for justification of 18FDG-PET examination

Kentaro Inoue, Ken Okada, Yasuyuki Taki, Ryoui Goto, Shigeo Kinomura, Tomohiro Kaneta, Hiroshi Fukuda

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background/Aims: The serum tumor marker carbohydrate associated antigen 19-9 (CA19-9) has been used for screening for cancer, because its increase has been associated with many cancers. We aimed to evaluate the clinical value of positron emission tomography using F-18 fluorodeoxyglucose (18FDG- PET) that was prompted by increases of serum CA19-9 without findings on conventional imaging. Methodology: Twenty-two patients were retrospectively selected. Eleven were without a history of cancer and eleven had a history of cancer and were treated with curative intent. All 18FDG-PET findings were compared with the findings of histopathology by surgery or biopsy, or clinical follow-up for at least 1 year. Results: We found only two true positive cases, and eleven cases without a cancer history included 10 true negatives and one false positive. Conclusions: Increases in serum CA19-9 are caused by many benign conditions. Increases of CA19-9 without findings on conventional imaging do not justify 18FDG-PET examination, particularly in patients without a cancer history.

Original languageEnglish
Pages (from-to)46-49
Number of pages4
JournalHepato-Gastroenterology
Volume55
Issue number81
Publication statusPublished - 2008 Jan 1

Keywords

  • CA19-9
  • Fluorodeoxyglucose F18
  • Positron-emission tomography
  • Screening
  • Tumor markers

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Increase of serum CA19-9 level without an evident lesion on conventional imaging is insufficient for justification of 18FDG-PET examination'. Together they form a unique fingerprint.

Cite this